Trial – Syneos Health/Eli Lilly
Eli Lilly and Company are conducting a study on an investigational drug called XXXXXXXXX as a possible treatment for moderate-to-severe atopic dermatitis (AD). This study will also include 2 vaccines commonly used in adults with AD: meningococcal vaccines (MCV) and tetanus, diphtheria, and pertussis (Tdap).
To participate in your local study, please contact (949) 844-0442 or fill out the form below.
Protocol # J2T-MC-KGAK/DRM06-AD18
Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.